Data from the federal government shows that Mississippi consistently ranks in the top five in the nation for its rates of ...

The FDA is poised to issue a decision soon on KarXT, a potential first-in-class antipsychotic for schizophrenia. What should ...

When states legalize medical and recreational cannabis, fewer prescriptions for anxiety are filled, but more for depression ...

The use of antipsychotics for schizophrenia was associated with higher risk for severe cases of COVID-19 and non–COVID-19 respiratory infections but not mild infection.

The following research questions were investigated: How much cognitive impairment do antipsychotic drug-naive FEP patients ...

Although it might be an interesting study, there aren’t any randomized, controlled trials of antipsychotic medications for ...

This isn't the case for the other classes of medications that we included. We actually find suggestive evidence that cannabis ...

The long-term safety of TEV-‘749 and incidence of PDSS are also being evaluated in the SOLARIS open-label study (Period 2), with safety data topline readout expected in the first half of 2025.

The following is a summary of “Antipsychotic exposure and infection risk in people with schizophrenia spectrum disorders ...

But the healthcare system in the US still struggles to provide adequate care for those with serious mental illness ...

anti-anxiety medications, antipsychotics, stimulants, and mood stabilizers. These categories of medications are generally taken orally (by mouth). However, some categories mentioned above have varying ...

This is an extremely useful text for anyone involved in the use of antipsychotic drugs.' John M. Kane - Professor and Chairman, Department of Psychiatry, Donald and Barbara Zucker School of Medicine ...